首页 > 市场调查报告书 > 製药

神经疾病

市场调查报告书

商品编码

1624417

2024 年至 2031 年帕金森氏症治疗市场（依病患照护环境、通路、药物类别及地区划分）

Parkinson's Disease Treatment Market By Patient Care Setting, By Distribution Channel, By Drug Class, And Region for 2024-2031

出版日期: 2024年09月17日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

帕金森氏症治疗市场评估，2024-2031 年

这种疾病在老年人中更为常见，全球人口正在老化。随着人口老化，预计帕金森氏症患者的数量将会增加。随着越来越多的人意识到帕金森氏症，早期诊断变得越来越重要。预计2023年市场规模将超过52亿美元，2031年将达到99.1亿美元的估值。改善帕金森氏症症状的新药和新疗法的研发正在取得进展。政府对帕金森氏症研究的资助正在增加，这将促进新疗法的开发。预计 2024 年至 2031 年期间市场复合年增长率为 8.4%。帕金森氏症治疗市场：定义/概述帕金森氏症是一种导致行走困难的慢性神经系统疾病。影响包括手部震颤，心搏过缓，姿势不稳，以及肌肉和身体部位运动僵硬。其他症状包括心境恶劣、吞嚥困难、便秘、构音障碍、情绪变化、排尿问题、睡眠问题和皮肤问题。患者的活动和控制肌肉的能力也会受到影响。运动和非运动因素都会发挥作用。

未来几年，由于帕金森氏症的流行和人口老化，帕金森氏症治疗市场预计将扩大。政府对研究的支持以及对症多巴胺替代疗法左旋多巴的日益普及，也可能推动未来几年该产业的发展。此外，随着研究活动从帕金森氏症的症状治疗转向疾病改良疗法，未来几年将为帕金森氏症治疗领域的新发展提供充足的机会。存在一些可能阻碍市场扩大的限制和困难。替代药物的可用性可能会对市场造成限制。

帕金森氏症患者病率的上升以及老龄化人口的扩大如何促进帕金森氏症治疗市场的成长？

随着世界人口老化速度不断加快，帕金森氏症的盛行率也不断增加。这种神经退化性疾病的特征是运动控制逐渐丧失，并且通常随着年龄的增长而恶化。儘管其实际原因尚不清楚，但老化似乎在其发展中起着关键作用。人口老化趋势尤为明显，65岁以上人口数量大幅增加。这个年龄层的人特别容易罹患帕金森氏症，而老化是罹患这种疾病的最大风险因素之一。

医学知识的进步，加上公众意识的提高，使得帕金森氏症的诊断更加及时和准确。这种早期检测可以及时介入和实施适当的治疗方案，可能减缓疾病进展并改善患者的治疗效果。帕金森氏症的持续研究和开发工作正在产生有希望的成果，包括新药、新疗法，甚至外科手术的发现。这些突破性的治疗为患者带来了缓解症状和提高生活品质的希望。

世界各国政府越来越认识到帕金森氏症的社会经济成本，并为研究工作提供更多支持。这样的资金支持促成了突破性的发现并加速了新疗法的发展。儘管帕金森氏症通常只关注运动功能障碍，但治疗非运动症状的重要性越来越受到人们的认可。认知障碍、睡眠障碍和疼痛都是影响患者整体生活品质的重要因素。因此，现代治疗技术专注于治疗这些因素，以改善受影响个体的生活品质。

同时，新兴国家的医疗保健支出正在增加，对帕金森氏症的认识也在增强。这个蓬勃发展的行业为以前处于弱势的群体提供了扩大治疗选择和医疗知识的机会。此外，技术发展正在极大地改变帕金森氏症的治疗。远距医疗平台、穿戴式监测设备和人工智慧诊断工具提供了远距护理、追踪疾病发展和根据特定患者需求个人化治疗方法的新方法。这些技术有可能改变帕金森氏症的管理，使患者和医疗保健提供者都更加方便和有效率。

目前帕金森氏症治疗费用高昂且疗效有限，如何阻碍帕金森氏症治疗市场的成长？

帕金森氏症治疗的经济负担很重，可能会给患者带来问题，特别是在医疗预算有限或完全缺乏保险覆盖的地区。长期维持治疗通常需要药物和治疗费用，这可能会使个人和家庭陷入经济困难，并导致获得医疗服务的机会不公平。目前的药物疗法可以缓解症状，但不能解决导致帕金森氏症的根本神经过程。这些限制凸显了对药物的需求，这种药物不仅可以治疗症状，还可以减缓或阻止疾病进展。开发这样的药物不仅需要新的治疗技术，还需要更深入地瞭解疾病的原因。

虽然一些帕金森氏症药物可以有效抑制症状，但它们会引起运动障碍等不良副作用，这会对患者的生活品质产生重大影响。这些副作用可能会使患者不愿意坚持治疗方案，因此，寻找耐受性更好的药物的重要性就凸显出来了。缺乏可靠的诊断工具可能会阻碍帕金森氏症的早期发现，从而延迟干预并阻碍最佳治疗效果。能够检测生物标记和细微疾病症状的创新诊断技术对于帮助及时诊断和介入、改善患者预后至关重要。

儘管进行了大量研究，帕金森氏症的确切病因仍然未知。这种缺乏理解的情况阻碍了针对潜在病理机制的疾病改良药物的开发。更好地瞭解疾病机制对于确定新的治疗目标和开发更有效的治疗方法至关重要。接受过帕金森氏症管理培训的神经病学家和专科医务人员的短缺加剧了获得医疗服务的不平等，尤其是在贫困的农村地区。透过培训和远距医疗平台解决人力短缺问题可以帮助患者。

地理位置、社会经济水平和保险覆盖范围都会造成获得优质帕金森氏症治疗的机会差异。消除这些差异的努力包括改善医疗保健基础设施、启动外展计划以及争取让所有帕金森氏症患者平等接受治疗的政策。药物开发和审批过程受到严格的监管标准，因此将新药推向市场的时间很长且昂贵。简化监管管道、鼓励利害关係人合作、激发创新，都将有助于更快获得新药，使等待更有效治疗的患者受益。

The disease is more common among older adults, and the global population is aging. As the population ages, the number of people with Parkinson's disease is expected to increase. More people are becoming aware of Parkinson's disease, and there is a growing emphasis on early diagnosis. The growth of market size to surpass USD 5.2 Billion in 2023, to reach a valuation of USD 9.91 Billion by 2031. New medications and therapies are being developed that can help to improve the symptoms of Parkinson's disease. There is increasing government funding for research into Parkinson's disease, which is leading to the development of new treatments. The market is to grow at a CAGR of 8.4% from 2024 to 2031. Parkinson's Disease Treatment Market: Definition/ Overview Parkinson's disease is a chronic neurological illness that makes it difficult to walk. The effects include hand tremors, bradykinesia, postural instability, and rigidity in muscle and body component movements. Other symptoms of this condition include dysthymia, dysphagia, constipation, dysarthria, emotional changes, urine problems, sleep abnormalities, and skin problems. The patient's ability to move and regulate their muscles is also impacted. Both motor and non-motor factors affect it.

Over the upcoming years, the Parkinson's Condition Treatment Market is anticipated to rise due to the prevalence of the disease and the aging population. Government support for research and widespread L-Dopa use, a symptomatic dopamine replacement therapy & nigrostriatal system, are further factors that have likely grown the industry in the ensuing years. Additionally, in the future years, the Parkinson's disease treatment sector has access to rich new development opportunities as research activities transition from symptomatic treatment to Parkinson's disorder modifying treatment. Some limitations and difficulties may prevent the market from expanding. The availability of alternatives is anticipated to probably serve as a market restraint.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How is the Rising Prevalence of Parkinson's Disease Alongside the Expanding Geriatric Population Contributing to the Growth of the Parkinson's Disease Treatment Market?

As the global population ages at an unprecedented rate, the prevalence of Parkinson's disease rises. This neurodegenerative condition, which is marked by progressive loss of motor control, is increasingly being related to characteristics that worsen with age. While the actual reason remains unknown, the aging process appears to play an important part in its development. The demographic change toward an older population is especially striking, with a significant increase in people aged 65 and up. This age group is especially prone to Parkinson's disease, as age is one of the most major risk factors for its beginning.

Advances in medical knowledge, combined with increased public awareness, have resulted in more timely and accurate Parkinson's disease diagnosis. This early discovery enables rapid intervention and the implementation of appropriate treatment regimens, perhaps slowing the progression of the disease and improving patient outcomes. The ongoing research and development efforts in Parkinson's disease are producing encouraging results, with the discovery of novel drugs, therapies, and even surgical interventions. These breakthrough therapy approaches provide patients hope for better symptom control and a higher quality of life.

Governments throughout the world are increasingly acknowledging the socioeconomic cost posed by Parkinson's disease and devoting more support to research activities. This financial support enables groundbreaking discoveries and promotes the development of novel treatment options. While Parkinson's disease has generally been regarded solely through the lens of motor dysfunction, there is an increasing recognition of the relevance of treating its non-motor manifestations. Cognitive impairment, sleep difficulties, and pain are all key factors influencing patients' overall well-being. As a result, modern treatment techniques focus more on treating these components of the condition to improve the quality of life for those affected.

In parallel, emerging economies are seeing an increase in healthcare spending and greater awareness of Parkinson's disease. This booming industry provides chances for expanding treatment options and disseminating medical knowledge to previously disadvantaged communities. Furthermore, technological developments are transforming Parkinson's disease treatment. Telemedicine platforms, wearable monitoring devices, and AI-powered diagnostic tools provide novel ways to give care remotely, track illness development, and personalize treatment approaches to particular patient needs. These technologies have the potential to change Parkinson's disease management by making it more convenient and efficient for both patients and healthcare providers.

How does the High Cost Associated with Treatments and the Limited Efficacy of Current Therapies for Parkinson's Disease Serve as Barriers to the Growth of the Parkinson's Disease Treatment Market?

The financial burden associated with Parkinson's disease therapy can be significant, providing issues for patients, particularly in regions with limited healthcare budgets or those without complete insurance coverage. Medication and therapy costs, which are frequently necessary for long-term maintenance, can put individuals and families under financial duress, potentially leading to inequities in access to care. Although current medications relieve symptoms, they do not address the underlying neuronal processes that cause Parkinson's disease. This constraint emphasizes the critical need for medicines that not only treat symptoms but also delay or stop disease progression. Developing such medicines necessitates a more in-depth understanding of illness causes as well as novel therapeutic techniques.

While some Parkinson's disease treatments are effective in managing symptoms, they can cause unpleasant effects such as dyskinesia, which has a substantial influence on patients' quality of life. These adverse effects may discourage patients from following treatment plans, emphasizing the significance of finding drugs with better tolerability profiles. The lack of reliable diagnostic tools hinders early detection of Parkinson's disease, delaying intervention and possibly hampering optimal treatment outcomes. Innovative diagnostic techniques capable of detecting biomarkers or subtle illness symptoms are critical for aiding timely diagnosis and intervention, thereby improving patient outcomes.

Despite substantial research, the exact cause of Parkinson's disease remains unknown. This lack of understanding impedes the development of disease-modifying medicines that address the underlying pathological mechanisms. Increasing our understanding of disease mechanisms is critical for identifying new therapeutic targets and developing more effective treatment options. A lack of neurologists and specialist healthcare providers educated in Parkinson's disease management exacerbates inequities in access to care, particularly in impoverished rural areas. Addressing the manpower deficit through training efforts and telemedicine platforms can help patients

Geographic location, socioeconomic level, and insurance coverage all contribute to disparities in access to high-quality Parkinson's disease treatment. Efforts to eliminate these disparities include improving healthcare infrastructure, launching outreach programs, and campaigning for policies that encourage equitable access to care for all Parkinson's patients. The strict regulatory criteria that govern drug development and approval processes contribute to long durations and expensive costs when bringing new therapies to market. Streamlining regulatory channels, encouraging stakeholder collaboration, and promoting innovation can all help to accelerate the availability of new medications, which benefits patients who are waiting for more effective treatment alternatives.

Category-Wise Acumens

How do Increased Patient Visits to Hospitals and the Specialized Expertise within the Hospital Pharmacies Segment Contribute to Driving Growth in the Parkinson's Disease Treatment Market?

The Hospital Pharmacies segment is showing substantial growth in the Parkinson's Disease Treatment Market and is expected to continue its growth throughout the forecast period. Because Parkinson's disease is a degenerative condition that generally necessitates long-term management and periodic adjustments to medication regimens, patients regularly visit hospitals to meet with neurologists or movement disorder experts. Hospital pharmacies, which are conveniently placed within healthcare facilities, have become the major option for people to fill prescriptions and obtain pharmaceuticals prescribed by their healthcare professionals.

Hospital pharmacies frequently hire pharmacists with specialized understanding in neurology and Parkinson's disease care. These specialists play an important role in assuring proper pharmaceutical selection, dose optimization, and patient education on treatment adherence and potential side effects. Their experience improves the quality of care for those with Parkinson's disease. Hospital pharmacies provide a wide range of Parkinson's disease treatments, such as levodopa-carbidopa formulations, dopamine agonists, MAO-B inhibitors, and anticholinergic drugs. This extensive range enables healthcare practitioners to personalize treatment regimens to specific patients' needs, improving symptom control while reducing side effects.

Certain Parkinson's disease drugs, such as levodopa-carbidopa intestinal gel (LCIG) and apomorphine infusion therapy, necessitate particular formulations and administration methods. Hospital pharmacies are equipped to combine and dispense these pharmaceuticals, allowing patients to get advanced treatment choices that may not be available in retail or community pharmacies. Hospitals frequently use a multidisciplinary approach to Parkinson's disease management that includes neurologists, movement disorder experts, nurses, pharmacists, and other healthcare professionals. This collaborative care strategy enables a thorough evaluation, personalised therapy planning, and continuing monitoring of patients' therapeutic responses and illness progression. Hospital pharmacies play an important role in this framework by promoting communication and collaboration among various parts of the healthcare team. In addition to drug distribution, hospital pharmacists may provide ancillary services such as medication treatment management, medication reconciliation, and adherence counseling. These services improve patient safety, treatment adherence, and clinical results for those living with Parkinson's disease.

How do the Effectiveness in Symptom Management and wide Acceptance, along with the Long-Standing Use of the Carbidopa/Levodopa Segment, Contribute to Driving the Growth of the Parkinson's Disease Treatment Market?

The Carbidopa/Levodopa segment is significantly leading in the Parkinson's Disease Treatment Market. Carbidopa/levodopa combination therapy is regarded as the gold standard for the treatment of Parkinson's disease symptoms, specifically motor fluctuations and dyskinesia. Levodopa, a precursor of dopamine, passes the blood-brain barrier and converts to dopamine, restoring the brain's low dopamine levels. Carbidopa improves the efficacy of levodopa by reducing its peripheral metabolism, enabling more levodopa to enter the brain. Carbidopa/levodopa is a key component of Parkinson's disease treatment due to its efficacy in symptom control.

Carbidopa/levodopa has been used for decades and is well-known as a first-line treatment for Parkinson's disease. Its efficacy and safety profile have been thoroughly researched and validated in clinical trials and real-world clinical settings. Healthcare practitioners are confident in prescribing carbidopa/levodopa, which contributes to its widespread adoption and ongoing use in clinical practice. Carbidopa/levodopa is available in a variety of dosage forms, including immediate-release tablets, extended-release formulations, orally disintegrating tablets, and orally disintegrating films. This varied spectrum of formulations enables healthcare practitioners to adjust treatment regimens to individual patients' needs, improving symptom control while avoiding undesirable effects like motor fluctuations and dyskinesia.

Carbidopa/levodopa can be taken alone or in conjunction with other drugs, such as dopamine agonists, MAO-B inhibitors, and COMT inhibitors, to produce the best symptom management results. Combination therapy tactics try to target many elements of Parkinson's disease pathology, and may be especially useful in treating motor fluctuations and dyskinesia caused by long-term levodopa administration.

Carbidopa/levodopa medication helps many Parkinson's patients improve their symptoms and overall quality of life. Its effectiveness in treating motor symptoms such as tremor, stiffness, and bradykinesia can result in high patient satisfaction and adherence to treatment regimens. Patient preference for carbidopa/levodopa therapy, combined with its low side effect profile, contributes to its sustained success in the Parkinson's Disease Treatment Market. Overall, the significant growth shown in the Carbidopa/Levodopa category indicates the medication's critical role in effectively controlling Parkinson's disease symptoms and enhancing patients' quality of life. Its lengthy history of usage, established efficacy, numerous formulation possibilities, and patient acceptance all contribute to its continued use in Parkinson's disease treatment regimens.

Parkinson's Disease Treatment

Market Report Methodology

Country/Region-wise Acumens

How does the Advanced Healthcare Infrastructure and Robust Research and Development in North America Influence the Demand for Treatments in the Parkinson's Disease Treatment Market?

North America is estimated to dominate the parkinson's disease treatment market during the forecast period. The Asia-Pacific area is undergoing a demographic change marked by a rapidly aging population. With rising life expectancy and changing lifestyle habits, the prevalence of age-related neurological illnesses like Parkinson's disease is increasing, creating a demand for effective treatment alternatives.

Economic development and increased disposable incomes in Asia Pacific countries are driving up healthcare spending. Increased investment in healthcare infrastructure, research, and access to breakthrough therapies helps to grow the Parkinson's Disease Treatment Market in this region. Emerging economies in Asia Pacific, including China, India, and South Korea, offer considerable growth potential for pharmaceutical businesses and healthcare providers. These countries are seeing fast urbanization, growing middle-class populations, and increased knowledge of neurological illnesses, which is driving demand for Parkinson's disease therapies.

Governments in Asia Pacific are prioritizing healthcare reform and investing in disease management programs. Public health campaigns, drug subsidies, and attempts to increase healthcare access all help to drive the Parkinson's Disease Treatment Market forward by increasing patient access to treatment alternatives. North America is home to several leading pharmaceutical and biotechnology businesses that specialize in neurological illnesses, such as Parkinson's disease. These corporations use their experience in medicine discovery, marketing, and distribution to dominate the regional market and propel therapeutic innovation forward.

Patients in North America have access to a wide range of specialist healthcare services, such as movement disorder clinics, rehabilitation facilities, and multidisciplinary care teams. This comprehensive approach to Parkinson's disease care guarantees that patients receive individualized treatment strategies as well as holistic support throughout their disease journey.

The United States, in particular, devotes a considerable portion of its GDP to healthcare spending, demonstrating a strong commitment to disease prevention, treatment, and research. This significant investment creates a favorable environment for pharmaceutical companies and healthcare providers, adding to North America's supremacy in the Parkinson's Disease Treatment Market.

How do the Rapidly Aging Population and Growing Healthcare Expenditure in the Asia Pacific Region Contribute to the Rapid Expansion of the Parkinson's Disease Treatment Market?

The Asia Pacific region is estimated to exhibit the highest growth within the Parkinson's Disease Treatment Market during the forecast period. The Asia-Pacific area is undergoing a demographic change marked by a rapidly aging population. With rising life expectancy and changing lifestyle habits, the prevalence of age-related neurological illnesses like Parkinson's disease is increasing, creating a demand for effective treatment alternatives. Economic development and increased disposable incomes in Asia Pacific countries are driving up healthcare spending. Increased investment in healthcare infrastructure, research, and access to breakthrough therapies helps to grow the Parkinson's Disease Treatment Market in this region.

Emerging economies in Asia Pacific, including China, India, and South Korea, offer considerable growth potential for pharmaceutical businesses and healthcare providers. These countries are seeing fast urbanization, growing middle-class populations, and increased knowledge of neurological illnesses, which is driving demand for Parkinson's disease therapies. Governments in Asia Pacific are prioritizing healthcare reform and investing in disease management programs. Public health campaigns, drug subsidies, and attempts to increase healthcare access all help to drive the Parkinson's Disease Treatment Market forward by increasing patient access to treatment alternatives.

As Parkinson's disease becomes more well known in the Asia Pacific region, more sufferers seek medical attention and diagnosis for their symptoms. Improved disease recognition and diagnosis rates contribute to greater demand for Parkinson's disease therapies, which drives regional market growth. The Asia Pacific region has a huge and increasingly aging population, particularly in Japan, South Korea, and China. With aging being a prominent risk factor for Parkinson's disease, the growing elderly population provides a large patient pool for Parkinson's disease therapies, driving market expansion.

Competitive Landscape

The Parkinson's Disease Treatment Market is competitive, with significant pharmaceutical companies such as AbbVie Inc., GlaxoSmithKline plc, Novartis AG, and Teva Pharmaceutical Industries Ltd. These prominent players conduct considerable research and development initiatives to create new therapeutic methods and improve existing therapy alternatives. Strategic collaborations, partnerships, and acquisitions are common techniques for increasing market presence and improving product portfolios. Furthermore, competition in this market is driven by elements such as efficacy, safety, pricing, and market access tactics, all of which strive to suit the different demands of both patients and healthcare professionals.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the Parkinson's Disease Treatment Market include:

GSK, Merck, Novartis, Teva, Boehringer Ingelheim, Impax, Abbvie, Valeant Pharmaceuticals, Lundbeck, Sun Pharma, Wockhardt, Acadia, UCB.
Parkinson's Disease Treatment Market Latest Developments:
In March 2024, AbbVie Announced positive results from a Phase 2 clinical trial evaluating a new investigational drug for the treatment of Parkinson's disease. The drug showed promise in improving motor symptoms and potentially slowing disease progression.
In April 2024, Boehringer Ingelheim Presented data at a major neuroscience conference on a next-generation levodopa formulation with potentially sustained release properties. This could offer longer-lasting symptom control and reduce the need for frequent dosing.
In February 2024, Impax Laboratories Received FDA approval for a generic version of Rytary, a levodopa-carbidopa combination drug used for Parkinson's disease treatment. This can increase treatment options and potentially lower medication costs.

1 INTRODUCTION OF GLOBAL PARKINSON'S DISEASE TREATMENT MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL PARKINSON'S DISEASE TREATMENT MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL PARKINSON'S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING

5.1 Overview
5.2 Clinics
5.3 Hospitals

6 GLOBAL PARKINSON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
6.2 Hospital Pharmacies
6.3 Retailer Pharmacies
6.4 Online Pharmacies

7 GLOBAL PARKINSON'S DISEASE TREATMENT MARKET, BY DRUG CLASS

7.1 Overview
7.2 Carbidopa/Levodopa
7.3 Dopamine Receptor Agonists
7.4 Mao Inhibitors
7.5 Comt Inhibitors
7.6 Anticholinergics
7.7 Other Drugs

8 GLOBAL PARKINSON'S DISEASE TREATMENT MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Argentina
8.6 Rest of the World
- 8.6.1 Latin America
- 8.6.2 Middle East and Africa

9 GLOBAL PARKINSON'S DISEASE TREATMENT MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES

10.1 GSK
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Merck
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Novartis
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Teva
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Boehringer Ingelheim
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Impax
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Abbvie
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Valeant Pharmaceuticals
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Lundbeck
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Sun Pharma
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments
10.11 Wockhardt
- 10.11.1 Overview
- 10.11.2 Financial Performance
- 10.11.3 Product Outlook
- 10.11.4 Key Developments
10.12 Acadia
- 10.12.1 Overview
- 10.12.2 Financial Performance
- 10.12.3 Product Outlook
- 10.12.4 Key Developments
10.13 UCB
- 10.13.1 Overview
- 10.13.2 Financial Performance
- 10.13.3 Product Outlook
- 10.13.4 Key Developments